{"schema_version":"secwatch.filing_event.v1","accession":"0001842952-24-000050","form_type":"8-K","ticker":"CNTX","cik":"0001842952","company_name":"Context Therapeutics Inc.","filed_at":"2024-07-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.851915+00:00","generated_at":"2026-05-31T22:14:08.462241+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Context Therapeutics acquires CT-95 (mesothelin x CD3 T cell engager) for $3.75M","bullets":["Acquired CT-95 from Link (assignment for benefit of creditors) for $3.75M upfront payment.","CT-95 is IND-cleared; Phase 1 trial expected to initiate in Q1 2025.","Targets mesothelin, prevalent in ovarian, lung, and pancreatic cancers.","Advancement through Phase 1 dose escalation to be funded with existing cash."],"urls":{"canonical":"https://secwatch.observer/filing/0001842952-24-000050","json":"https://secwatch.observer/filing/0001842952-24-000050.json","markdown":"https://secwatch.observer/filing/0001842952-24-000050.md","text":"https://secwatch.observer/filing/0001842952-24-000050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842952/000184295224000050/0001842952-24-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842952/000184295224000050/cntx-20240709.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T22:14:08.462241+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}